
4D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage development for wet age-related macular degeneration and prepares to begin a Phase 3 trial in diabetic macular edema.
Speaking at a Bank of America event, David Kirn, co-founder, president and CEO of 4D Molecular Therapeutics, described the company as a “leader in next generation AAV gene therapy” and said 4D-150 is in Phase 3 for wet AMD and “soon to be in Phase 3” for diabetic macular edema, or DME.